Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoadjuvant Operable Breast Cancer
Conditions
Neoadjuvant Operable Breast Cancer
Trial Timeline
Jan 1, 2015 → Sep 1, 2020
NCT ID
NCT02400567About Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib
Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib is a phase 2 stage product being developed by Pfizer for Neoadjuvant Operable Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02400567. Target conditions include Neoadjuvant Operable Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02400567 | Phase 2 | Completed |
Competing Products
4 competing products in Neoadjuvant Operable Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Trastuzumab Emtansine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6) | Adlai Nortye | Phase 1 | 25 |
| Pembrolizumab, Eftilagimod alfa | Immutep | Phase 2 | 44 |